X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
olaparib (585) 585
index medicus (487) 487
oncology (411) 411
humans (404) 404
ovarian cancer (294) 294
female (291) 291
poly polymerase (251) 251
cancer (245) 245
olaparib maintenance therapy (206) 206
chemotherapy (185) 185
mutation (169) 169
breast cancer (166) 166
ovarian neoplasms - drug therapy (146) 146
homologous recombination (144) 144
tumors (143) 143
parp inhibitor (138) 138
dna repair (134) 134
open-label (117) 117
animals (115) 115
parp inhibitors (115) 115
ovarian neoplasms - genetics (108) 108
dna damage (102) 102
pharmacology & pharmacy (99) 99
care and treatment (97) 97
deoxyribonucleic acid--dna (96) 96
poly polymerase inhibitors - therapeutic use (95) 95
repair (93) 93
cell line, tumor (88) 88
antineoplastic agents - therapeutic use (87) 87
ovarian-cancer (87) 87
breast-cancer (86) 86
middle aged (84) 84
research (84) 84
brca1 (83) 83
therapy (83) 83
brca1 protein - genetics (82) 82
poly polymerase inhibitors (82) 82
brca (81) 81
cancer therapies (81) 81
brca2 protein - genetics (75) 75
monosaccharides (75) 75
phthalazines - pharmacology (75) 75
sugars (75) 75
clinical trials (74) 74
synthetic lethality (74) 74
aged (73) 73
poly polymerase inhibitors - pharmacology (73) 73
parp (72) 72
piperazines - pharmacology (71) 71
genetic aspects (70) 70
maintenance therapy (70) 70
ovarian neoplasms - pathology (70) 70
article (69) 69
phthalazines - therapeutic use (69) 69
antineoplastic agents - pharmacology (67) 67
patients (66) 66
adult (65) 65
combination (65) 65
double-blind (65) 65
survival (65) 65
health aspects (64) 64
male (64) 64
piperazines - therapeutic use (64) 64
phase-i (63) 63
analysis (62) 62
inhibitors (62) 62
mice (62) 62
endocrine system diseases (61) 61
dna-repair (60) 60
obstetrics & gynecology (60) 60
bevacizumab (59) 59
carcinoma (59) 59
dna-damage (59) 59
cells (57) 57
fallopian-tube (57) 57
ribose (57) 57
apoptosis (56) 56
brca1 protein (56) 56
poly polymerases - metabolism (56) 56
cell biology (55) 55
phthalazines - administration & dosage (54) 54
medicine & public health (53) 53
mutations (53) 53
piperazines - administration & dosage (51) 51
genes, brca1 (50) 50
pegylated liposomal doxorubicin (50) 50
drug therapy (49) 49
antineoplastic combined chemotherapy protocols - therapeutic use (48) 48
polymerase (48) 48
brca2 (47) 47
breast (46) 46
metastasis (46) 46
negative breast-cancer (46) 46
review (46) 46
hematology, oncology and palliative medicine (45) 45
prostate cancer (45) 45
neoplasms - drug therapy (44) 44
germ-line mutation (43) 43
inhibition (43) 43
medical research (43) 43
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC CANCER, ISSN 1471-2407, 03/2019, Volume 19, Issue 1, pp. 198 - 11
BackgroundDespite multimodality treatments including neurosurgery, radiotherapy and chemotherapy, glioblastoma (GBM) prognosis remains poor. GBM is classically... 
PLUS CONCOMITANT | SURVIVAL | RESECTION | GLIOMA | Glioblastoma | CONTINUAL REASSESSMENT METHOD | Radiosensitizer | Radiotherapy | MULTIFORME | TUMORS | RADIOSENSITIZATION | INHIBITION | Poly (ADP-ribose) polymerase (PARP) | ONCOLOGY | olaparib | EXTENT | Life Sciences | Cancer | Radiosensitizer, olaparib
Journal Article
Journal Article
BMC Cancer, ISSN 1471-2407, 01/2019, Volume 19, Issue 1, pp. 44 - 9
BackgroundPoly (ADP-ribose) polymerase inhibitors (PARPi) have become the first targeted therapies available in the treatment of patients with high-grade... 
Ovarian Cancer | BRCA1/2 | Synthetic lethality | Chemoresistance | PARP inhibitor | DNA repair pathway | HOMOLOGOUS RECOMBINATION DEFICIENCY | MECHANISMS | BRCA1 | OLAPARIB | REPAIR | ONCOLOGY | RIBOSE POLYMERASE PARP | COMMON | INHIBITORS | Chemotherapy | Usage | Care and treatment | Patient outcomes | Genetic aspects | Ovarian cancer | Cancer
Journal Article
BREAST CANCER RESEARCH, ISSN 1465-5411, 09/2019, Volume 21, Issue 1, pp. 104 - 14
Background Breast cancer remains as one of the most lethal types of cancer in women. Among various subtypes, triple-negative breast cancer (TNBC) is the most... 
DNA-DAMAGE RESPONSE | Olaparib | DRUG-RESISTANCE | OVARIAN-CANCER | Prexasertib | S-PHASE CHECKPOINT | CHK1 INHIBITION | LUNG-CANCER | REPAIR | RAD51 | CISPLATIN | ONCOLOGY | CHK1 and homologous recombination | CHEMORESISTANCE | TNBC | Care and treatment | Chemotherapy | Usage | Cancer cells | Breast cancer | Research | Cancer
Journal Article
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, ISSN 1756-9966, 05/2019, Volume 38, Issue 1, pp. 203 - 203
Journal Article
Journal of enzyme inhibition and medicinal chemistry, ISSN 1475-6366, 12/2019, Volume 34, Issue 1, pp. 150 - 162
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2019, Volume 145, Issue 9, pp. 2594 - 2596
Journal Article
JOURNAL OF THORACIC ONCOLOGY, ISSN 1556-0864, 10/2019, Volume 14, Issue 10, pp. 1743 - 1752
Introduction: Inhibitors of poly-(ADP)-ribose polymerase (PARP) are promising therapeutics for SCLC. We tested whether PARP inhibitor (PARPi) target engagement... 
Positron-emission tomography | SCLC | GERMLINE | RADIOTRACER | ADULTS | Talazoparib | COMBINATION | Poly(ADP-ribose) polymerase 1 inhibitors | TUMORS | CELL LUNG-CANCER | OLAPARIB | PARP1 EXPRESSION | CISPLATIN | ONCOLOGY | RESPIRATORY SYSTEM | Drug target engagement | PHASE-I
Journal Article
AAPS PharmSciTech, ISSN 1530-9932, 10/2019, Volume 20, Issue 7, pp. 1 - 13
Journal Article